AZNAstraZenecaRunning, no new patients
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 895 (final count)
- Started
- Oct 31, 2018
- Main results expected
- Jul 30, 2021
- Fully finished
- Feb 5, 2027
- Results posted
- Jun 15, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment
Measured over: Assessed from date of randomisation to data cut off (DCO1): 30Jul2021 (Approx. 2 years 9 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03732820 · record last updated 2026-08-18 · checked 2026-11-09 15:47 UTC